
- Gilead Sciences' (NASDAQ:GILD) remdesivir, Regeneron Pharmaceuticals' (NASDAQ:REGN) cocktail antibodies and
- Moderna's (NASDAQ:MRNA) vaccine candidate.
- BioNTech (NASDAQ:BNTX),
- Pfizer (NYSE:PFE),
- Dynavax Technologies (DVAX),
- Vaxart (NASDAQ:VXRT),
- GlaxoSmithKline (NYSE:GSK),
- Heat Biologics (NASDAQ:HTBX),
- Inovio Pharmaceuticals (NASDAQ:INO),
- Translate Bio (NASDAQ:TBIO),
- Heron Therapeutics (HRTX)
- Johnson & Johnson (JNJ),
- Arcturus Therapeutics (NASDAQ:ARCT), CSL Behring and Novavax (NASDAQ:NVAX). Treatment candidates are being worked on by privately-held CalciMedica, Amgen (NASDAQ:AMGN),
- Adaptive Biotechnologies (ADPT), Takeda Pharmaceutical (NYSE:TAK), CytoDyn (OTCQB:CYDY), Roche Holdings (OTCQX:RHHBY), Regeneron Pharmaceuticals, Tiziana Life Sciences (NASDAQ:TLSA), Vir Biotechnology (NASDAQ:VIR), Eli Lilly (NYSE:LLY), Sanofi (NASDAQ:SNY) and more.
News:
- (7/16/20) Dynavax (DVAX) and the Icahn School of Medicine at Mount Sinai have entered into a collaboration to develop a universal influenza vaccine. Mount Sinai's current work in this area is funded under a contract award as part of the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program. The Mount Sinai CIVICs team will evaluate a novel approach they have developed called chimeric hemagglutinin designed to protect against all strains of influenza in combination with Dynavax's CpG 1018TM adjuvant.
- (7/16/20) Heron Therapeutics (HRTX) announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with COVID-19. The study initiation follows clearance from the FDA of Heron's Investigational New Drug application for CINVANTI for the treatment of COVID-19.
No comments:
Post a Comment